CTLA4 and neoplasm: While several reports suggest that particularly inflamed tumors respond better to ICI8, it is controversial whether TH17–IL-17 inflammation could have an anti-tumor effect in melanoma, particularly during combined anti-PD-1 and anti-CTLA-4 therapy.